Resolving Mechanistic Heterogeneity Through Precision Medicine and Staged Intervention

The Skeptic's critique, while raising legitimate concerns about delivery and heterogeneity, fundamentally mischaracterizes the proposed therapeutic strategy by treating it as a monolithic intervention rather than a precision medicine framework. The eRNA approach is explicitly designed for the genetically defined subset of ALS-FTD patients where TDP-43 mutations create identifiable pathological RNA interactomes—the approximately 5% of ALS cases with TARDBP mutations and the significant fraction of FTD cases with GRN mutations that secondarily alter TDP-43 function. I have never claimed this approach applies uniformly to all ALS-FTD patients. Rather, I propose a stratified therapeutic strategy where eRNA interventions target the subset with characterized pathological RNA-TDP-43 interactions, while independent approaches address sporadic ALS through distinct mechanisms such as proteostasis stabilization or stress granule modulation. The delivery concerns, while valid for AAV-PHP.eB in adult humans, ignore the rapidly evolving landscape of CNS RNA delivery technologies.

The Skeptic's critique, while raising legitimate concerns about delivery and heterogeneity, fundamentally mischaracterizes the proposed therapeutic strategy by treating it as a monolithic intervention rather than a precision medicine framework. The eRNA approach is explicitly designed for the genetically defined subset of ALS-FTD patients where TDP-43 mutations create identifiable pathological RNA interactomes—the approximately 5% of ALS cases with TARDBP mutations and the significant fraction of FTD cases with GRN mutations that secondarily alter TDP-43 function. I have never claimed this approach applies uniformly to all ALS-FTD patients. Rather, I propose a stratified therapeutic strategy where eRNA interventions target the subset with characterized pathological RNA-TDP-43 interactions, while independent approaches address sporadic ALS through distinct mechanisms such as proteostasis stabilization or stress granule modulation. The delivery concerns, while valid for AAV-PHP.eB in adult humans, ignore the rapidly evolving landscape of CNS RNA delivery technologies. Lipid nanoparticles (LNPs) have demonstrated robust mRNA delivery to the CNS in non-human primates at clinically relevant doses (PMID:35294805), and conjugating these to antibodies against transferrin receptor enables BBB transcytosis (PMID:34619125). These platforms are already in clinical development for other neurological conditions and represent near-term translational opportunities rather than distant theoretical possibilities. The Skeptic's reliance on mouse-specific AAV capsid limitations to dismiss the entire delivery modality reflects a failure to appreciate platform evolution. ## Addressing Heterogeneity Through Mechanistic Subsetting The critical insight from the Skeptic's heterogeneity argument is that it supports rather than undermines the precision therapeutic approach. ALS-FTD represents a final common clinical phenotype arising from multiple distinct pathogenic mechanisms, all converging on TDP-43 dysfunction. Just as we would not expect a single chemotherapy to treat all cancers, we should not expect a single TDP-43-targeted therapy to address all ALS-FTD subtypes. The disease heterogeneity I acknowledged in Round 2—where familial ALS with TDP-43 mutations proceeds through the pathological RNA interactome while sporadic ALS may originate from distinct upstream insults—actually predicts differential therapeutic responses that can be prospectively identified through biomarker s

Debate provenance: derived from debate `DA-2026-04-11-093252-90e0375b` on question: TDP-43 phase separation therapeutics for ALS-FTD. Consensus signal: domain_expert, falsifier, skeptic, synthesizer, theorist discussed the mechanism terms AAV, ALS, BBB, CNS, FTD, GRN, Heterogeneity, Intervention. Novelty signal: skeptic-discussed-with-qualified-concession.